CHILDHOOD ASTHMA MANAGEMENT PROGRAM CONTINUATION STUDY/PHASE 2

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This protocol is for the Childhood Asthma Management Program Continuation Study/Phase 2 (CAMPCS/2), A 3.25 year observational follow-up study of the children enrolled in the Childhood Asthma Management Program (CAMP). CAMP was a multicenter randomized clinical trial designed to determine the effects of three treatments (albuterol alone, albuterol with inhaled corticosteroid (ICS), albuterol with inhaled non-steroid) in 1041 children (randomized at ages 5-13 years) with mild asthma on pulmonary function during a 3.5-5.5 year treatment phase. The cohort has been followed in a 4.5 year observational phase (CAMP Continuation Study, CAMPCS) to determine longer term effects of the treatments on lung and based on national guidelines. CAMPCS/2 is designed to follow the cohort for 4 additional years in to early adulthood, when the patients will be 17-26 years (55% >21 years). Childhood asthma can result in significant lung disease in adulthood and possibly the development of chronic obstructive pulmonary disease (COPD). None of the long-term follow-up studies of childhood asthma have had the close follow-up needed to define determinants of outcomes in inflammatory agents on outcomes.